Australian biotech company Prima BioMed (ASX: PRR) will present research into its lead immuno-oncology candidate, IMP321, at the 2nd Annual Cancer Immunotherapy Conference in San Francisco next month.
The drug is in Phase II development against metastatic breast cancer and also in Phase I development in melanoma in combination with Keytruda (pembrolizumab), according to a report from Van Leeuwenhoeck Research analyst Marcel Wijma.
Prima acquired the rights to IMP321 when it bought the privately held French immunotherapy company Immutep in 2014, becoming a front-runner in LAG-3 technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze